Percentages of Vaccination Coverage Required to Establish Herd Immunity against SARS-CoV-2

Other authors

Agència de Salut Pública de Catalunya, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. Ciber of Epidemiology and Public Health (CIBERESP), Madrid, Spain

Departament de Salut

Publication date

2024-01-26T09:45:07Z

2024-01-26T09:45:07Z

2022-05-08



Abstract

COVID-19 vaccination coverage; SARS-CoV-2; Anti-SARS-CoV-2 herd immunity


Cobertura de vacunación COVID-19; SARS-CoV-2; Inmunidad colectiva anti-SARS-CoV-2


Cobertura de vacunació COVID-19; SARS-CoV-2; Immunitat de grup anti-SARS-CoV-2


The pandemic associated with SARS-CoV-2 is a worldwide public health challenge. The WHO has proposed to achieve 70% COVID-19 vaccination coverage in all countries by mid-2022. Nevertheless, the prevention strategy based on COVID-19 vaccination and other applied prevention measures has not been sufficient to prevent SARS-CoV-2 epidemic waves. This study assessed the vaccination coverage that would be required to establish herd immunity against SARS-CoV-2, taking into account virus transmissibility (Ro values from 1.1 to 10) and COVID-19 vaccination effectiveness. The study found that high percentages of vaccination coverage and high levels of vaccination effectiveness are necessary to block the transmission of Omicron and other SARS-CoV-2 variants with greater infectious capacity. COVID-19 vaccination programs could establish herd immunity against SARS-CoV-2, with Ro values ranging from 3 to 10 and levels of COVID-19 vaccination effectiveness of 70-100%. Factors reducing COVID-19 vaccination effectiveness (emergent variants, infections among vaccinated individuals, high risk individuals) and factors increasing SARS-CoV-2 transmissibility (close settings) increased the percentages of vaccination coverage that would be required to establish herd immunity. Two measures should be implemented to establish herd immunity against SARS-CoV-2: (1) achieve ≥ 90% COVID-19 vaccination coverage in all countries worldwide, and (2) increase the effectiveness of COVID-19 vaccines in preventing Omicron infection to at least 88%.

Document Type

Article


Published version

Language

English

Publisher

MDPI

Related items

Vaccines;10(5)

https://doi.org/10.3390/vaccines10050736

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)